Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data From VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data From VOLITION Study and Presentation at American Society of Anesthesiologists Conference
Trevena宣布完成对来自VOLITION研究的OLINVYK持续呼吸监测数据的初步分析并在美国麻醉师学会会议上发表的演讲
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced completion of initial analysis of OLINVYK continuous respiratory monitoring data from the VOLITION study.
专注于为中枢神经系统疾病患者开发和商业化新药的生物制药公司特雷维纳公司(纳斯达克代码：TRVN)今天宣布，完成了对OLINVYK持续呼吸监测数据的初步分析。
The VOLITION study, a real-world, open-label, multi-site study, assessed the potential impact of OLINVYK on respiratory, gastrointestinal (GI), and cognitive function outcomes in the postoperative setting. The Company previously announced GI and cognition data from the study.
这项意志力研究是一项真实世界、开放标签、多地点的研究，评估了OLINVYK对术后环境中呼吸、胃肠道(GI)和认知功能结果的潜在影响。该公司此前公布了这项研究的GI和认知数据。